Baseline clinical characteristics of all ART-naive HIV+ study participants, the subset of HIV+ participants that initiated ART, and HIV-seronegative controls (HCs)
| . | HIV+ (n = 43), median (interquartile range) . | HIV+/ART (n = 30), median (interquartile range) . | HC (n = 29), median (interquartile range) . | P . | |
|---|---|---|---|---|---|
| HIV+ vs HC . | HIV+/ART vs HC . | ||||
| Age, y | 38 (33-43) | 36 (33-42) | 47 (43-58) | .0002 | .0002 |
| CD4+ T cells/μL | 187 (47-383) | 69 (21-229) | 623 (432-879) | < .0001 | < .0001 |
| CD4+ T cells, % | 15 (5-26) | 8 (2-19) | 45 (40-52) | < .0001 | < .0001 |
| CD8+ T cells/μL | 539 (351-977) | 457 (290-798) | 291 (230-470) | .0005 | .023 |
| CD8+ T cells, % | 58 (45-66) | 60 (49-68) | 22 (17-30) | < .0001 | < .0001 |
| Serum IL-7, pg/mL | 24.8 (19.3-36.3) | 30.0 (22.3-40.5) | 15.3 (12.3-19.6) | < .0001 | < .0001 |
| Log10 plasma HIV-1 RNA, copies/mL | 4.76 (3.98-5.15) | 5.02 (4.48-5.41) | NA | NA | NA |
| . | HIV+ (n = 43), median (interquartile range) . | HIV+/ART (n = 30), median (interquartile range) . | HC (n = 29), median (interquartile range) . | P . | |
|---|---|---|---|---|---|
| HIV+ vs HC . | HIV+/ART vs HC . | ||||
| Age, y | 38 (33-43) | 36 (33-42) | 47 (43-58) | .0002 | .0002 |
| CD4+ T cells/μL | 187 (47-383) | 69 (21-229) | 623 (432-879) | < .0001 | < .0001 |
| CD4+ T cells, % | 15 (5-26) | 8 (2-19) | 45 (40-52) | < .0001 | < .0001 |
| CD8+ T cells/μL | 539 (351-977) | 457 (290-798) | 291 (230-470) | .0005 | .023 |
| CD8+ T cells, % | 58 (45-66) | 60 (49-68) | 22 (17-30) | < .0001 | < .0001 |
| Serum IL-7, pg/mL | 24.8 (19.3-36.3) | 30.0 (22.3-40.5) | 15.3 (12.3-19.6) | < .0001 | < .0001 |
| Log10 plasma HIV-1 RNA, copies/mL | 4.76 (3.98-5.15) | 5.02 (4.48-5.41) | NA | NA | NA |